Neutrophil-lymphocyte index as prognostic factor for overall survival and disease-free survival in breast cancer patients

We investigated the prognostic influence of androgen receptor (AR) on breast cancer. AR status was assessed using immunohistochemistry with tissue microarrays from 395 operable primary breast cancer patients who received curative surgery. The Kaplan–Meier estimator was used to analyze the survival rates and a log-rank test was used to determine the significance of the differences in survival. The Cox proportional hazards model was used to calculate the hazard ratio (HR) and the 95% confidence interval (CI) of survival. There were 203 (51.4%) subjects with a low expression of AR, and 192 patients (48.6%) with a high expression rate. The high AR expression group showed superior overall survival (p = 0.047) and disease-free survival (p = 0.004) when compared with the low AR expression group. The high AR expression group showed superior systemic recurrence-free survival when compared with the low AR expression group (p = 0.027). AR was an independent prognostic factor for both overall survival (HR, 0.586; 95% CI, 0.381–0.901; p = 0.015) and disease-free survival (HR, 0.430; 95% CI, 0.274–0.674; p < 0.001). A high AR expression was a significant favorable prognostic factor only in the subgroups with positive hormone receptors (HRc) and negative human epidermal growth factor receptor 2 (HER2) when considering disease-free survival (p = 0.026). The high AR expression group was significantly associated with superior overall survival and disease-free survival when compared with the low AR expression group with breast cancer patients. AR was a significant independent prognostic factor for both overall survival and disease-free survival. The prognostic impact of AR was valid in the HRc(+)/HER2(−) subtype when considering disease-free survival. These findings suggest the clinical usefulness of AR as a prognostic marker of breast cancer in clinical settings.

Download Full-text

Abstract PS6-44: The significance of body mass index and absolute lymphocyte count as a prognostic factor for disease-free survival in Korean breast cancer patients

10.1158/1538-7445.sabcs20-ps6-44 ◽

2021 ◽

Author(s):

Sung Min Ko

Keyword(s):

Breast Cancer ◽

Body Mass Index ◽

Prognostic Factor ◽

Cancer Patients ◽

Lymphocyte Count ◽

Disease Free Survival ◽

Absolute Lymphocyte Count ◽

Breast Cancer Patients ◽

Free Survival ◽

Disease Free

Download Full-text

312 The impact of the Sentinel Node concept on overall survival, disease-free survival and axillary recurrence of breast cancer patients

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(10)70338-4 ◽

2010 ◽

Vol 8 (3) ◽

pp. 149

Author(s):

J.L. Fougo ◽

F. Castro ◽

P. Reis ◽

L. Giesteira ◽

T. Dias ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Sentinel Node ◽

Cancer Patients ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Free Survival ◽

Sentinel Node Concept ◽

The Impact ◽

Disease Free

Download Full-text

Young Age is not an Ominous Prognostic Factor in Breast Cancer Patients

Tumori Journal ◽

10.1177/030089168707300305 ◽

1987 ◽

Vol 73 (3) ◽

pp. 233-235 ◽

Cited By ~ 15

Author(s):

Giuseppe Muscolino ◽

Corrado Villani ◽

Amedeo Vittorio Bedini ◽

Alberto Luini ◽

Bruno Salvadori

Keyword(s):

Breast Cancer ◽

Prognostic Factor ◽

Cancer Patients ◽

Young Women ◽

Survival Rates ◽

Disease Free Survival ◽

Young Age ◽

Breast Cancer Patients ◽

Free Survival ◽

Disease Free

Analysis of a series of 137 women 20–30 years of age, operated for breast carcinoma, excluding patients pregnant, lactating or with inflammatory cancer, showed that disease-free survival rates were similar and not lower than those reported for a large series of 716 breast cancer patients of all ages, treated and followed at the same Institute. Ten-year disease-free survival rates for the two series of 137 young women and 716 patients of all ages were 43.7% and 47.1% respectively. Even when considering the subgroups of patients with and without nodal axillary involvement, the corresponding figures for the two series considered were 72.6% vs. 72.1% (N−) and 25.1% vs. 24.5% (N+). It can be concluded that young age cannot be considered as an unfavorable prognostic factor.

Download Full-text

The prognostic importance of triple negative breast cancer: A population based study in India

Journal of Clinical Oncology ◽

10.1200/jco.2009.27.15_suppl.e22219 ◽

2009 ◽

Vol 27 (15_suppl) ◽

pp. e22219-e22219

Author(s):

B. S. Ajaikumar ◽

R. Rao ◽

J. Prabhu ◽

J. D. Kulkarni ◽

P. K ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Regression Analysis ◽

Cancer Patients ◽

Triple Negative ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Free Survival ◽

Node Status ◽

Disease Free

e22219 Background: Triple-negative (ER-negative, PR-negative, HER2/neu negative) breast cancer has distinct clinical and pathologic features, and is a clinical problem because of its typically high grade, relatively poor prognosis, aggressive behavior and lack of targeted therapies leaving chemotherapy as the mainstay of treatment. This study envisaged to analyse the influence of triple negativity status on survival and disease free survival in prospective cohort of breast cancer patients. Methods: Breast tumors of 215 women aged 30–75, diagnosed from 2004 were tested for ER, PR and HER2 positivity by immunohistochemistry and correlated with clinical outcomes such as recurrence, disease free survival and overall survival using Kaplan Meiers Survival analysis and Coxs regression analysis. The study cohort was followed up for 60 months or until death whichever was earlier. Results: Triple negativity significantly influenced disease free survival (46 ± 3, 41, 52) vs. non triple negative cohort (mean ± SE; 95%CI, 37 ± 2; 32, 40) and log rank = 2.1, p = 0.04. However triple negativity did not influence overall survival in months (56 ± 0; 55, 56) vs. non triple negative cohort (43 ± 1; 42, 45), (log rank = 1.78, p = 0.16). However, the mean disease free survival was (45 ± 7; 32, 58) months for patients >40 years age vs (37 ± 4; 33, 39) for patients < 40 years of age (log rank = 2.87, p =0.02). Stage of disease, node status, grade and menopausal status did not influence disease free survival significantly. However, Cox regression analysis did not predict significant effects of triple negativity on overall survival or disease free survival when controlled for confounding factors such as age, node status, stage etc Conclusions: Our observations suggest that triple negativity can significantly affect progression of breast cancer in Indian breast cancer patients and longer follow up is necessary (10 years) to determine its effects on survival. No significant financial relationships to disclose.

Download Full-text

Statin use and the development of bone metastasis in breast cancer patients.

Journal of Clinical Oncology ◽

10.1200/jco.2012.30.27_suppl.40 ◽

2012 ◽

Vol 30 (27_suppl) ◽

pp. 40-40 ◽

Cited By ~ 1

Author(s):

Gentry Teng King ◽

Jeong H. Yun ◽

Young K. Chae ◽

Matias E. Valsecchi ◽

Mark S. Morginstin

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Bone Metastasis ◽

Cancer Patients ◽

Disease Free Survival ◽

Breast Cancer Patients ◽

Free Survival ◽

Bony Metastasis ◽

Disease Free ◽

Statin Use

40 Background: The Mevalonic Acid Pathway has been implicated in the promotion of a microenvironment suitable for establishment of bony metastasis from breast cancer. The statins, which act on this pathway, have been shown to have in vitro antineoplastic activity against breast cancer. This study was designed to evaluate the association of statin use and development of bony metastasis in breast cancer patients. Methods: Medical records of patients treated for stage II-III breast cancer from 1999 to 2010 were retrospectively reviewed. Statin use was defined as medication use for at least 3 months in patients with no evidence of disease after initial diagnosis and treatment. The primary outcome was development of metastasis to bone. Secondary outcomes were overall survival, disease free survival and other sites of distant metastasis. Results: A total of 841 patients were included in the study of which 223 used statins. Both unadjusted and multivariate analysis adjusted for age, race, grade, stage, BRCA status, showed that patients on statins had a significantly lower incidence of metastasis to bone (OR 0.49, 95% CI 0.25-0.96, p=0.04). Adjusted analysis for other sites showed a trend towards decreased incidence of metastasis for statin users, but was not statistically significant (95% CI 0.39-1.08, p=0.10). Overall survival was increased in statin users with mean survival of 66.45 +/- 2.48 months versus non-users 58.78 +/ - 1.41 months (p=0.05). Statin users had significantly longer disease free survival with a mean of 63.65 +/- 2.49 months versus 53.96 +/- 1.42 months in non statin users (p=0.00). Conclusions: The use of statin drugs in patients with breast cancer was significantly associated with decreased incidence of metastasis to bone, but not to other distant sites. The role of statins in chemoprevention of bone metastasis should be further explored.

Download Full-text